Together with the data described above, our results demonstrated that REV-ERBα function is reprogrammed in prostate cancer progression from activating tumorigenic kinase signaling and metabolic programs in adenocarcinoma to activating LP gene programs in NEPC. This evidence concerns the gene NR1D1 and prostate carcinoma.